Pharmaceuticals, Biotechnology and Life Sciences
First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support…
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the…
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted…
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) — Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for…
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), Aligos a clinical stage biopharmaceutical…
Company anticipates commencement of trading on Nasdaq effective October 29, 2024 under the symbol “GELS”NEW YORK, Oct. 28, 2024 (GLOBE…
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage…
Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) — Polyrizon Ltd. (the “Company” or “PLRZ”), a development stage biotech company specializing…
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron Oral presentation highlights findings that patients…
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing…